Clinical trials: Prostate Disease
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis)
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
- Trial name
- NCT07856017
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Prostate Cancer, mCRPC
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
Primary Efficacy Endpoint Radiographic Progression-Free Survival (rPFS): rPFS is defined as the time from randomization to radiographic disease progression (PD), as assessed by Blinded Independent Central Review (BICR) according…
- Trial name
- NCT07853209
- Testing
- [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone
- Where
- 8 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- FutureChem
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Androgen Deprivation Therapy, Prostate Cancer
Autonomic and Renal Contributions to Hypertension With ADT
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer.
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction
- Trial name
- ARCH (NCT07848828)
- Testing
- Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Prostate Cancer (Diagnosis), Prostatic Neoplasms
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
Current prostate cancer diagnosis relies on MRI-targeted biopsy combined with a 12-core systematic biopsy. The systematic component is a major driver of overdiagnosis of insignificant cancer and biopsy-related morbidity, and…
- Trial name
- FLASH (NCT07846592)
- Testing
- Ex vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)
- Volunteers
- 450 people
- Sponsor
- Shanghai East Hospital
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC.
- Trial name
- NCT04191096
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 234 sites in United States, Australia and 27 more
- Volunteers
- 1,251 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer (Diagnosis)
CascadeDiagnose Prostate MRI
This multicenter clinical study is evaluating CascadeDiagnose Prostate MRI, an artificial-intelligence software tool that analyzes standard prostate MRI scans-T2-weighted, diffusion-weighted, and ADC images-to help radiologists…
- Trial name
- NCT07844304
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Cardiovascular Diseases
CV CARE: CardioVascular Care in PC Patients
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a…
- Trial name
- NCT06202820
- Testing
- CV Care Program
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Prostate Disease
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
The purpose of this study is to test the safety, tolerability, and effectiveness of the investigational drug nivolumab (Opdivo™) in combination with high dose radiation.
- Trial name
- NCT03543189
- Testing
- Nivolumab, Brachytherapy, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer (Diagnosis)
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
Prostate cancer is one of the most common malignancies in men. Currently, due to the limited diagnostic accuracy of existing imaging tests, there is a risk of missed diagnosis or unnecessary prostate biopsy.
- Trial name
- NCT07690306
- Where
- 6 sites in United States, China
- Volunteers
- 1,500 people
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancers
PRostate Cancer Enhanced Diagnosis by Calibration Technology
The CARE® Phantom system is a medical device system that is being developed has been designed to enable the quantitative measurement of the apparent diffusion coefficient (ADC) in the prostate of patients undergoing a…
- Trial name
- PREDICT (NCT06607783)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Gold Standard Phantoms
Prostate Cancer (Diagnosis)
Advanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)
In 2019 the UK National Institute for Health and Care Excellence (NICE) updated its guidelines to recommend Magnetic Resonance Imaging (MRI) for all patients prior to biopsy as it permits the targeted sampling of suspicious…
- Trial name
- ASPIRE MS (NCT07808528)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- University College, London
Prostate Cancer, Renal Cancer
HPI Effect in Robotic Urological Surgery on AKI
It is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after robot-assisted urological surgery.
- Conditions
- Prostate Cancer, Renal Cancer, Urologic Diseases
- Trial name
- NCT06051162
- Testing
- BP management with HPI guidance
- Where
- South Korea
- Volunteers
- 124 people
- Sponsor
- Ewha Womans University Mokdong Hospital
PSMA-related Disease, Prostate Cancer
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer…
- Conditions
- PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690970
- Testing
- 68Ga/18F-PSMA/PSFA
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Intermediate Risk Prostate Cancer (Diagnosis), Prostate Cancer
Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT07674225)
- Testing
- Prostate radical radiotherapy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC.
- Trial name
- NCT04934722
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 24 sites in China
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Androgen Deprivation Therapy, Prostate Cancer
Contributions to Hypertension With Androgen Deprivation Therapy
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer.
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction
- Trial name
- ARCH (NCT05700903)
- Testing
- Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
- Trial name
- STOP-NEPC (NCT07639086)
- Testing
- Sacituzumab Tirumotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University